1177 Stock Overview
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 1177 from our risk checks.
Sino Biopharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.77 |
| 52 Week High | HK$4.41 |
| 52 Week Low | HK$2.29 |
| Beta | 0.52 |
| 1 Month Change | -8.28% |
| 3 Month Change | -4.15% |
| 1 Year Change | -36.18% |
| 3 Year Change | -66.91% |
| 5 Year Change | -46.04% |
| Change since IPO | 10,099.57% |
Recent News & Updates
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings
Apr 21
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Recent updates
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings
Apr 21What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 20Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon
Dec 18Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate
Nov 17We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?
May 26Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued
Jan 22Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet
Dec 03Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Oct 19Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02
Sep 03These 4 Measures Indicate That Sino Biopharmaceutical (HKG:1177) Is Using Debt Reasonably Well
Aug 27Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 38% Undervaluation?
Jul 14Shareholder Returns
| 1177 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 18.4% | 8.5% | 5.2% |
| 1Y | -36.2% | -15.9% | -9.1% |
Return vs Industry: 1177 underperformed the Hong Kong Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 1177 underperformed the Hong Kong Market which returned -9.1% over the past year.
Price Volatility
| 1177 volatility | |
|---|---|
| 1177 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.8% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 1177 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1177's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 25,806 | Eric S. Y. Tse | www.sinobiopharm.com |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines comprising Qingkeshu tablets, Focus V capsules, Annike injection, and Anyue capsules; liver disease medicines, including Tianqing ganmei injection and Runzhong dispersible tablets; and respiratory system medicines, such as Tianqing suchang suspension for inhalation and Tianyun for injection.
Sino Biopharmaceutical Limited Fundamentals Summary
| 1177 fundamental statistics | |
|---|---|
| Market cap | HK$50.79b |
| Earnings (TTM) | HK$2.00b |
| Revenue (TTM) | HK$28.30b |
25.5x
P/E Ratio1.8x
P/S RatioIs 1177 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1177 income statement (TTM) | |
|---|---|
| Revenue | CN¥26.20b |
| Cost of Revenue | CN¥4.99b |
| Gross Profit | CN¥21.21b |
| Other Expenses | CN¥19.36b |
| Earnings | CN¥1.85b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 80.95% |
| Net Profit Margin | 7.05% |
| Debt/Equity Ratio | 32.0% |
How did 1177 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield46%
Payout RatioDoes 1177 pay a reliable dividends?
See 1177 dividend history and benchmarks| Sino Biopharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Jun 11 2024 |
| Dividend Pay Date | Jul 05 2024 |
| Days until Ex dividend | 44 days |
| Days until Dividend pay date | 68 days |
Does 1177 pay a reliable dividends?
See 1177 dividend history and benchmarks